Levalbuterol
Sponsors
Sumitomo Pharma America, Inc., Henry Ford Health System, Fahim Khorfan, MD, Sanofi, University of Illinois at Chicago
Conditions
Acute AsthmaAsthmaCOPDChronic Obstructive Pulmonary DiseaseHyperkalemiaOxygen ConsumptionSepsisShock
Phase 2
A Safety and Tolerability Study of Arformoterol Tartrate Inhalation Solution in Pediatric Subjects
CompletedNCT00583947
Start: 2008-01-31End: 2008-12-31Updated: 2012-02-22
Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma
CompletedNCT01312961
Start: 2011-03-31End: 2012-10-31Updated: 2017-06-08
Phase 3
Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma
CompletedNCT00073840
Start: 2002-12-31End: 2003-06-30Updated: 2012-02-22
A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma
CompletedNCT00809757
Start: 2008-12-31End: 2013-06-30Updated: 2014-07-28
Phase 4
A Pilot Study to Determine the Most Effective Dose of Arformoterol for Treating Acute Asthmatic Patients
TerminatedNCT00819637
Start: 2009-01-31End: 2009-11-30Updated: 2023-05-24
Effect of Nebulized Bronchodilators on Heart Rate
CompletedNCT01151579
Start: 2008-12-31End: 2009-11-30Updated: 2015-10-23
Aerosolized Beta-Agonist Isomers in Asthma
CompletedNCT02170532
Start: 2007-07-31End: 2009-07-31Updated: 2014-08-13
Levalbuterol Compared to Albuterol Regarding Cardiac Side Effects and Potassium Lowering Effects.
NCT05173584
Start: 2021-11-04End: 2021-12-31Target: 30Updated: 2021-12-30